Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 4;17(1):313.
doi: 10.1186/s13098-025-01834-1.

Glycaemic control, low levels of high-density lipoprotein, and high cardiovascular risk are associated with cardiovascular autonomic neuropathy

Affiliations

Glycaemic control, low levels of high-density lipoprotein, and high cardiovascular risk are associated with cardiovascular autonomic neuropathy

Tina Okdahl et al. Diabetol Metab Syndr. .

Abstract

Background: Cardiovascular autonomic neuropathy (CAN) is a life-threatening complication associated with diabetes but may also be present without diabetes. A glycaemic threshold for autonomic impairment is not yet established. The purpose of this study was to compare CAN status in people with and without diabetes and to investigate which factors contributed the most to the presence and severity of CAN.

Methods: We included 240 participants from three different cohorts: non-diabetic people (n = 40), people with overweight or obesity with or without prediabetes (n = 100), and people with type 2 diabetes (n = 100). All participants underwent cardiovascular autonomic reflex tests using the Vagus™ device, and clinical variables, including age, sex, body mass index, blood pressure, HbA1c, blood lipid profile, and cardiovascular risk score, were recorded.

Results: In total, 14% without and 42% with diabetes had CAN. HbA1c had the most significant influence on CAN scores, with a cutpoint of 45.5 mmol/l corresponding to established prediabetes (sensitivity: 0.66; specificity: 0.71). In people with HbA1c levels below the cutpoint, those with CAN had lower levels of high-density lipoprotein (HDL) (1.1 vs. 1.4 mmol/mol, p = 0.003) and higher cardiovascular risk scores (p < 0.001) compared to people without CAN. No differences in any of the investigated clinical factors were seen between people with HbA1c levels above the cutpoint with or without CAN.

Conclusions: In individuals with HbA1c levels below 45.5 mmol/l, both HDL levels and cardiovascular risk score were associated with CAN status. Therefore, it may be beneficial to screen for CAN in individuals susceptible to prediabetes, who also exhibit low HDL levels and a high cardiovascular risk.

Keywords: Cardiovascular autonomic neuropathy; Cardiovascular risk score; High-density lipoprotein; Prediabetes.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The studies were approved by the North Denmark Region Committee on Health Research Ethics (cohort 1: N-20190020 and cohort 3: N-20170045) and the Ethics Committee of the Capital Region of Denmark (cohort 2: H-18059188). Written informed consent was collected from all participants before initiation of any study-related activities. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Similar articles

References

    1. Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, Estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–93. - PMC - PubMed
    1. Spallone V, Ziegler D, Freeman R et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011 Oct 1 [cited 2023 Apr 5];27(7):639–53. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/dmrr.1239 - PubMed
    1. Ang L, Dillon B, Mizokami-Stout K et al. Cardiovascular autonomic neuropathy: A silent killer with long reach. Auton Neurosci. 2020;225. - PubMed
    1. Spallone V. Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes: what is defined, what is new, and what is unmet. Diabetes Metab J. 2019;43(1):3–30. - PMC - PubMed
    1. Andersen ST, Lauritzen T, Charles M, et al. Risk factors for the presence and progression of cardiovascular autonomic neuropathy in type 2 diabetes: ADDITION-Denmark. Diabetes Care. 2018;41(12):2586–94. - PubMed

LinkOut - more resources